A sensitizing regimen of amphetamine impairs visual attention in the 5-choice serial reaction time test: reversal by a D1 receptor agonist injected into the medial prefrontal cortex.

Full Abstract

Exposure to repeated, intermittent, escalating doses of amphetamine in rats disrupts information processing in several tasks. Some of these deficits, notably impaired attentional set shifting, may reflect altered prefrontal cortex function. This study examined the effects of repeated treatment with amphetamine on performance in the 5-choice serial reaction time test. This test measures sustained visual attention, a behavior that is known to require the prefrontal cortex. Rats were trained to respond to a brief light stimulus presented randomly in one of five spatial locations, with 100 trials per session. Once performance had stabilized rats were treated with escalating doses of amphetamine (three injections per week for 5 weeks at 1-5 mg/kg per week); testing was continued on nondrug days, and for several weeks of withdrawal. During the amphetamine-treatment and withdrawal phases accuracy of responding was unaffected, but errors of omission increased. Lengthening the stimulus duration abolished this effect. Reducing the stimulus duration also reduced response accuracy and this effect was more marked in amphetamine-treated rats. Both reduced accuracy, and increased omissions, seen in amphetamine-treated rats were reversed by injecting the D1 receptor agonist SKF38393 into the medial prefrontal cortex. This treatment also prevented the decline in accuracy in control animals that resulted from reducing the stimulus duration. These results, indicating that exposure to amphetamine induces a long-lasting deficit in visual attention, add to a growing list of deficits suggesting that amphetamine-sensitized state may model the cognitive deficit state in schizophrenia. The reversal of these deficits by a D1 receptor agonist provides further evidence that prefrontal D1 dopamine receptors are involved in cognition, and may be a potential target for treatment of impaired cognition in schizophrenia.

Learn Faster Today Improve your study skills

Author information

Author/s: Fletcher, Paul J (PJ); Tenn, Catherine C (CC); Sinyard, Judy (J); Rizos, Zoë (Z); Kapur, Shitij (S);

Affiliation: Section of Biopsychology, Centre for Addiction and Mental Health, Toronto, ON, Canada. Paul_Fletcher(-atsign-)camh.net

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology), published in United States. (Language: eng)

Reference: 2007-May; vol 32 (issue 5) : pp 1122-32

Dates: Created 2007/04/17; Completed 2007/06/05;

PMID: 17047670, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology
Amphetamine - pharmacology
Animals
Attention - drug effects; physiology
Cognition - drug effects; physiology
Dopamine - metabolism
Dopamine Agonists - pharmacology
Dopamine Uptake Inhibitors - pharmacology
Dose-Response Relationship, Drug
Male

Male
Neuropsychological Tests
Photic Stimulation
Prefrontal Cortex - drug effects; metabolism
Rats
Rats, Sprague-Dawley
Reaction Time - drug effects; physiology
Receptors, Dopamine D1 - agonists; metabolism
Substance Withdrawal Syndrome - metabolism; physiopathology
Visual Perception - drug effects; physiology

Associated Chemicals: Dopamine Agonists (0) ; Dopamine Uptake Inhibitors (0) ; Receptors, Dopamine D1 (0) ; Amphetamine (300-62-9) ; Dopamine (51-61-6) ; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (67287-49-4)

These are the highest related articles currently in the database:

See 100+ related articles.